The portal for rare diseases and orphan drugs

ABSTRACT

Orphan drugs are the stepchildren of the pharmaceutical industry. These medicinal products that are used primarily for the prevention or treatment of life‑threatening or debilitating rare diseases have restricted markets and thus limited profitability. As a consequence, the pharmaceutical industry has little interest in developing and marketing these drugs which are intended for patients who suffer from rare conditions.

KEYWORDS

• Webwise

Showing references and in-text citations exactly as published.

Cite this article

RELATED ARTICLES

Matched on section and article type within this issue of J Pharmacol. Pharmacother..

• Article · VOLUME 4, ISSUE 2C‑section, formula may disrupt ‘good’ gut bacteria in babiesSivagnanam G · pp. 166–7Same type: Article
• Article · VOLUME 4, ISSUE 2Modulation of multidrug resistance 1 expression and function in retinoblastoma cells by curcuminSeethalakshmi Sreenivasan, Sathyabaarathi Ravichandran, Umashankar Vetrivel · pp. 103–109Same type: Article
• Article · VOLUME 4, ISSUE 2Evaluation of acute physiological and molecular alterations in surgically developed hypothyroid Wistar ratsMaulik Patel, Vinay Mishra, Vaibhavi Pawar, Ramchandran Ranvir, Rajesh Sundar, Rajas Dabhi · pp. 87–93Same type: Article
• Article · VOLUME 4, ISSUE 2Assessment of proarrhythmic activity of chloroquine in in vivo and ex vivo rabbit modelsShailaja B. Khobragade, Pankaj Gupta, Prashant Gurav, Girish Chaudhari, Madhumanjiri M. Gatne · pp. 116–124Same type: Article